Monitoring the plasma concentration of high-dosage of methotrexate during chemotheraphy for osteosarcoma and its clinical significance
10.3781/j.issn.1000-7431.2008.05.018
- Author:
Feng LIN
1
Author Information
1. Department of Oncology
- Publication Type:Journal Article
- Keywords:
Adverse drug reaction reporting systems;
Methotrexate;
Osteosarcoma;
Plasma concentration
- From:
Tumor
2008;28(5):440-442
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To monitor the blood concentration of high-dosage of methotrexate (HD-MTX) during chemotheraphy in the treatment of patients with osteosarcoma and discuss its clinical significance. Methods: Thirty-five patients with osteosarcoma who received high dosages of MTX (6 g/m2) for 50 times were involved in our study. The serum concentration of MTX was determined at each time point by improved RP-HPLC. The relationship between the serum concentration of MTX and the adverse reaction was analyzed. Results: The mean peak MTX level was (348.60 ± 200.47) μmol/L. The serum concentrations of MTX were significantly higher at 24 h and/or 48 h than safe levels (105 μmol to 106 μmol) in 15 cases (30%). The incidence rates of adverse reactions such as neutropenia, oral mucositis and rash were 40.0%, 33.3%, and 20%, respectively. Conclusion: There is significant variability in the MTX serum levels. The incidence rates of ad reactions are relatively higher in those patients whose 24-h and/or 48-h serum MTX concentrations are higher than the safe levels.
